Contineum Therapeutics (CTNM) Leerink Global Healthcare Conference 2026 summary

Strategic focus and company evolution

• Transitioned from platform-based drug discovery to advancing two clinical-stage assets and three ongoing clinical trials, focusing on neuroscience, inflammation, and immunology, with a particular emphasis on pulmonary fibrosis.

• PIPE-791 is positioned as a best-in-class LPA1 receptor inhibitor, with two key inflection points expected this year, including an exploratory pain study and external phase III data from BMS.

• PIPE-307, a brain-penetrant M1 receptor inhibitor, is partnered with J&J and in phase II for MDD, with clinical validation supporting its profile.

• The company is well-funded through mid-2029, prioritizing clinical development while maintaining a prolific in-house discovery engine.

• Partnerships for earlier-stage programs are considered, but focus remains on demonstrating success in IPF before seeking new collaborations.

PIPE-791 program and clinical differentiation

• PIPE-791 aims to optimize efficacy and convenience, achieving high receptor occupancy at low doses and offering once-daily dosing without titration.

• No hypotension signal observed in studies to date, differentiating it from BMS’s LPA1 antagonist, which requires dose titration due to hypotension risk.

• Phase II IPF study involves 108 subjects across three arms, with rigorous monitoring and allowance for background therapy over 26 weeks.

• Designed for future combination use, aiming to serve as a foundation for IPF therapy and facilitate easier patient adherence.

• KOLs express enthusiasm for the mechanism, robust clinical validation, and the potential for a once-daily, well-tolerated therapy.

PIPE-307 and partnership with J&J

• PIPE-307 is in phase II for MDD, with 124 patients and two dosing regimens, focusing on rapid onset of action and primary efficacy at day five.

• The program is central to J&J’s neuropsych portfolio, with potential for expansion into other depressive disorders.

• Safety and tolerability have been demonstrated in both healthy volunteers and patient populations, mitigating concerns about anticholinergic effects.

• Economics include $50M upfront, $1B+ in milestones, royalties starting in the low teens and ramping to 20% with co-funding options.